Influence of surgical removal and effect of levamisole on cytotoxic T-cell-mediated antitumor immunity in mice. 1983

K Gomi, and M Morimoto, and K Nomoto

In BALB/c mice bearing syngeneic fibrosarcoma Meth 1 tumors, effects of surgical removal and levamisole (LMS) on the growth of reinoculated Meth 1 cells were investigated. The growth of secondary tumors in mice with surgical removal of primary tumors was significantly inhibited as compared with that of secondary tumors in primary tumor-bearing mice without surgical removal. LMS (2.5 mg/kg) augmented the growth inhibition of secondary tumors. Its effect was significant only in mice bearing primary tumors without surgical removal. Cytotoxicity, which was detected in the spleen cells of Meth 1-bearing mice, was mediated by tumor-specific cytotoxic T-cells and augmented after surgical removal of the tumors. LMS augmented the cytotoxicity when it was administered before surgical removal of the tumors but not after surgical removal. The spleen cells of Meth 1-bearing mice in the last stage of tumor development did not exhibit cytotoxicity, but rather exhibited suppressor activity on the in vitro generation of cytotoxicity. In this stage, effect of LMS was not detected. For the induction of cytotoxic T-cells in vitro, the cooperation of nylon wool-nonadherent cells and antigen-presenting cells appeared to be necessary. Nylon wool-adherent cells exhibited the suppressor activity. LMS stimulated the activity of nonadherent cells and partially modulated the suppressor activity of adherent cells. These effects of LMS were suggested to result in the augmentation of the cytotoxicity of the spleen cells and the growth inhibition of the secondary tumors in Meth 1-bearing mice.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005354 Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed) Fibrosarcomas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012513 Sarcoma, Experimental Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA. EHS Tumor,Sarcoma, Engelbreth-Holm-Swarm,Sarcoma, Jensen,Experimental Sarcoma,Experimental Sarcomas,Sarcomas, Experimental,Engelbreth-Holm-Swarm Sarcoma,Jensen Sarcoma,Sarcoma, Engelbreth Holm Swarm,Tumor, EHS
D013154 Spleen An encapsulated lymphatic organ through which venous blood filters.
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

K Gomi, and M Morimoto, and K Nomoto
August 1976, Clinical and experimental immunology,
K Gomi, and M Morimoto, and K Nomoto
March 1976, Cancer research,
K Gomi, and M Morimoto, and K Nomoto
August 1973, The New England journal of medicine,
K Gomi, and M Morimoto, and K Nomoto
October 1981, Nihon Gan Chiryo Gakkai shi,
K Gomi, and M Morimoto, and K Nomoto
July 1974, Journal of the National Cancer Institute,
K Gomi, and M Morimoto, and K Nomoto
January 2005, Journal of immunotherapy (Hagerstown, Md. : 1997),
K Gomi, and M Morimoto, and K Nomoto
July 1969, Journal of the National Cancer Institute,
K Gomi, and M Morimoto, and K Nomoto
October 1977, Acta medica Okayama,
K Gomi, and M Morimoto, and K Nomoto
November 1999, Immunopharmacology and immunotoxicology,
K Gomi, and M Morimoto, and K Nomoto
April 1987, The Japanese journal of experimental medicine,
Copied contents to your clipboard!